mcas and tirzepatide Not all GLP-1s work the same way for MCAS., Most patients do better on Tirzepatide, the dual incretin with both GLP-1 GIP receptor agonists. But some mast cells just respond better to semaglutide. GLP-1s in MCAS with Dr.

Tirza Trim Injection contains Tirzepatide , a modern once-weekly injectable medicine used for Type 2 Diabetes and weight management

Utilizing a functional approach to medical weight loss, GLP-1s help patients achieve their weight loss goals in a healthy, sustainable way

The Cardiovascular biology of glucagon-like peptide-1

Patients should be encouraged to: Follow a balanced, portion-controlled diet emphasising whole grains, vegetables, lean proteins, and healthy fats Engage in regular physical activity (at least 150 minutes of moderate-intensity exercise weekly, as per NICE guidance) [3] Stay well-hydrated to minimise gastrointestinal side effects Avoid excessive alcohol consumption , which can impair glucose regulation Patient safety advice includes recognising when to seek medical attention: Contact your GP or diabetes nurse if experiencing persistent nausea/vomiting preventing adequate nutrition or hydration Contact NHS 111 or seek urgent medical advice for severe abdominal pain (potential pancreatitis or gallbladder disease, though rare) Report visual changes or symptoms of diabetic retinopathy progression Seek emergency care (A&E) for persistent vomiting with reduced urine output, or for persistent hyperglycaemia with ketones Attend scheduled follow-up appointments for HbA1c monitoring (typically at 36 months) Patients should be reassured that gradual glucose improvement is expected and appropriate , and that working collaboratively with their healthcare team optimises outcomes whilst minimising risks